



BiOkuris

# BK001

Experience relief from gas and bloating and restore a healthy gut microbiota with our unique solution

**BK001 IS INTENDED TO HELP WITH:**

**Regularization** /normalization of intestinal transit and stool evacuation


**Relief** of gas-related symptoms such as bloated feeling, flatulence and abdominal pain

**Normalization** of the intestinal function

## A UNIQUE MECHANISM OF ACTION


### Simethicone

A chemically inert mixture of polydimethylsiloxane and silica (CAS No. 8050-81-5)



### Chitin-glucan

A novel ingredient derived from mycelium, patented by KitoZyme composed of two types of polysaccharide chains linked in a 3d structure: chitin and beta-glucan.



### Action

Antifoaming effect favoring fast gas elimination

### Action

Effect on stool consistency, stool frequency, quality of evacuation and intestinal flora



**Favoring gas elimination**



**Improving stool consistency**





**Restoring a balanced microbiota**

# EXCEPTIONAL RESULTS VIA MULTIPLE CLINICAL, IN VITRO, AND IN VIVO STUDIES

**BK001** (medical device class IIa) is intended to be used in the symptomatic treatment of gas-related gastro-intestinal disorders

## Clinical study

**Clinical benefits in improving symptoms associated with the presence of gas confirmed in post marketing**



## Clinical study

**BK001 and IBS (irritable bowel syndrome)**



- Abdominal pain
- Bloating
- Dyschesia and other defecation problems
- Flatulence


## User test

**Efficacy on Intestinal troubles vs. competition**

Stool symptoms improvement after 1 week



After 4 weeks, decrease of each gastrintestinal symptom intensity in the BK001 group: Abdominal pain/discomfort, flatulence, bloating, borborygmi and in a lower range nausea



**Proven benefits of simethicone and the long-lasting effect of our prebiotic**

In vitro



In vivo

PPAR $\gamma$

Results indicate that the significant anti-inflammatory effect observed for BK001 may involve at least in part the induction of PPAR $\gamma$

## About BiOkuris

BiOkuris has developed the next generation of medical nutrition products tailored to the unmet medical needs of patients with chronic intestinal diseases such as IBD, IBS and Candidiasis. BiOkuris is part of the KitoZyme Group.

[www.biokuris.com](http://www.biokuris.com) – [info@biokuris.com](mailto:info@biokuris.com)

© April 2023, BiOkuris – All right reserved.  
The information contained herein is based on data know to KitoZyme or its affiliates at the time of preparation of this document. This is business-to-business information intended for distributors and is not intended for the final users or consumers.

